SPARC support the expansion of cord blood stem cells in vitro

Nanofiber Expansion of Umbilical Cord Blood Hematopoietic Stem Cells

Background The aim of this study was the ex vivo expansion of Umbilical Cord Blood hematopoietic stem cells on biocompatible nanofiber scaffolds. Materials and Methods CD133+ hematopoietic stem cells were separated from umbilical cord blood using MidiMacs (positive selection) system by means of monocolonal antibody CD133 (microbeads) subsequently, flowcytometry method was done to asses...

Expansion of Non-Enriched Cord Blood Stem/Progenitor Cells CD34+ CD38- Using Liver Cells

Many investigators have used xenogeneic, especially murine stromal cells and fetal calf serum to maintain and expand human stem cells. The proliferation and expansion of human hematopoietic stem cells in ex vivo culture were examined with the goal of generating a suitable protocol for expanding hematopoietic stem cells for patient transplantation. Using primary fetal liver cells, we established...

Comparison of Neonatal and Adult Mice-derived Sertoli Cells in Support of Expansion of Mouse Spermatogonial Stem Cells In vitro

nanofiber expansion of umbilical cord blood hematopoietic stem cells

background the aim of this study was the ex vivo expansion of umbilical cord blood hematopoietic stem cells on biocompatible nanofiber scaffolds. materials and methods cd133+ hematopoietic stem cells were separated from umbilical cord blood using midimacs (positive selection) system by means of monocolonal antibody cd133 (microbeads) subsequently, flowcytometry method was done to assess the pur...

Epigenetic reprogramming induces the expansion of cord blood stem cells.

Cord blood (CB) cells that express CD34 have extensive hematopoietic capacity and rapidly divide ex vivo in the presence of cytokine combinations; however, many of these CB CD34+ cells lose their marrow-repopulating potential. To overcome this decline in function, we treated dividing CB CD34+ cells ex vivo with several histone deacetylase inhibitors (HDACIs). Treatment of CB CD34+ cells with th...